✦ LIBER ✦

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS-RAF Mutations

✍ Scribed by Zimmer, L.; Barlesi, F.; Martinez-Garcia, M.; Dieras, V.; Schellens, J. H. M.; Spano, J.-P.; Middleton, M. R.; Calvo, E.; Paz-Ares, L.; Larkin, J.; Pacey, S.; Venturi, M.; Kraeber-Bodere, F.; Tessier, J. J. L.; Eberhardt, W. E. E.; Paques, M.; Guarin, E.; Meresse, V.; Soria, J.-C.

Book ID: 125520097
Publisher: American Association for Cancer Research
Year: 2014
Tongue: English
Weight: 613 KB
Volume: 20
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-14-0341

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

243 Phase 1 (Ph1) Clinical and Pharmacod

243 Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors

✍ Bahleda, R.; Zimmer, L.; Garcia, M. Martinez; Dieras, V. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phase I and pharmacokinetic/pharmacodyna

Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors

✍ Kazunori Honda, Noboru Yamamoto, Hiroshi Nokihara… 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 242 KB

26 ORAL Phase Ib and pharmacodynamic stu

26 ORAL Phase Ib and pharmacodynamic study of the MEK inhibitor AZD6244 (ARRY-142886) in patients with advanced solid malignancies

✍ A. Adjei; R.B. Cohen; W.A. Franklin; J. Molina; S. Hariharan; E. Temmer; S. Brow 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 82 KB

Phase I clinical, pharmacokinetic and ph

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

✍ Razak, A R A; Hotte, S J; Siu, L L; Chen, E X; Hirte, H W; Powers, J; Walsh, W; 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 308 KB

Phase I safety, pharmacokinetic, and pha

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

✍ Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 362 KB

Phase I dose-escalation and -expansion s

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 925 KB